NATALIZUMAB HIGH TITER

那他珠单抗高滴度

• 批准号: 7719064
• 负责人: HEIDI J CRAYTON
• 金额: $ 1.64万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719064
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Purpose; Relapse; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; immunogenicity; natalizumab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to evaluate the immunogenicity of natalizumab high titer material administered intravenously to subjects with relapsing forms of MS. The secondary objective of this study is to evaluate the safety of natalizumab high titer material

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的目的是评估静脉内对具有复发形式的MS的受试者静脉内施用的Natalizumab高滴度材料的免疫原性。这项研究的次要目的是评估纳塔尔苏单抗高滴度材料的安全性